HYBIO: Acetate Atosiban Injection has obtained marketing authorization in Vietnam

HYBIO announced that the company has received the "Drug Registration Certificate" issued by the Drug Administration of the Ministry of Health of Vietnam, granting marketing approval for its product "Atosiban Acetate Injection" in Vietnam. This medication is suitable for pregnant women with indications of preterm labor, used to delay imminent preterm birth, with good clinical efficacy and minimal side effects. The marketing approval of this drug will further enrich the company's overseas product pipeline and expand its overseas market. The company will actively promote the sales of this drug in overseas markets to enhance its international brand influence and overall competitiveness